Patients Treated with ARIKAYCE plus macrolide-based background regimen had meaningfully larger improvements in QOL-B respiratory score
SKYSCRAPER-01 is ongoing and the study remains blinded to patients and investigators
India is committed to eliminating Lymphatic Filariasis by 2027, three years ahead of the global target through mission mode, multi partner, multi sector targeted drive
The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite
Nous-209 has been developed using the Nouscom's viral vector platform
Study efficacy measures will include the expression of dystrophin protein and motor function.
AUR101, with a good ADME/PK profile and high bioavailability, has demonstrated inhibition of IL-17A in whole blood from psoriasis patients
Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival
Subscribe To Our Newsletter & Stay Updated
